Heart failure patients with moderate ejection fractions may benefit from CRT

Early findings from a Medtronic, Inc. (NYSE: MDT) sponsored study show heart failure patients with moderate ejection fractions, over 35 percent, may receive comparable benefits from cardiac resynchronization therapy (CRT) as compared to those with low ejection fractions of equal to or less than 35 percent. A retrospective analysis from the PROSPECT (Predictors of Response to CRT) study, the largest CRT post-market clinical study of its kind with primary endpoints measuring echocardiographic predictors of CRT response, suggests the potential for CRT to benefit more than 1 million heart failure patients worldwide who have an ejection fraction greater than 35 percent and are not currently indicated to receive CRT therapy.

“While more research is needed, this analysis shows the potential value of CRT for a broader spectrum of heart failure patients,” said Eugene Chung, M.D., director of the Heart Failure Program at The Christ Hospital, Ohio Heart and Vascular Center in Cincinnati, Ohio, and lead investigator of the PROSPECT study. “Regardless of their ejection fraction, patients in this study had similar outcomes indicating ejection fraction alone may not be a good measure of a patient’s response to CRT.”

When compared at six months post implant, the CRT patients with moderate and severe heart failure (NYHA class III and IV status) and wide QRS duration (the time required for the heart muscle to contract, in this case 130 milliseconds or more), had the following corresponding results.

• Sixty-three percent of CRT patients with ejection fractions over 35 had an improved clinical composite response (based on vital status, NYHA changes, heart failure hospitalizations, patient assessments, and discontinuation of CRT), as compared to 70 percent in patients with ejection fractions at or below 35 percent.
• Fifty-one percent of CRT patients with ejection fractions over 35 percent had a decrease in heart size (LVESV) greater than 15 percent as compared to 58 percent for those with ejection fractions at or below 35 percent.

“These results are promising and identify a new, critical research need to prove that CRT can have similar benefits to a broader group of patients that don’t meet the current indications,” said Marshall Stanton, M.D., vice president of clinical research for the Cardiac Rhythm Disease Management business at Medtronic. “Bringing the significant benefits of CRT in improving mortality, quality of life and overall cardiac function to more patients is an exciting prospect worthy of further exploration.”

http://www.medtronic.com/